Incyte (INCY) is a Biotechnology company. Incyte commercializes Jakafi/Jakafi XR (ruxolitinib) for myelofibrosis, polycythemia vera, and GVHD, and Opzelura cream for atopic dermatitis and vitiligo. Newer heme/oncology brands include Niktimvo, Minjuvi/Monjuvi, and Zynyz. It was founded in 1991, is headquartered in Wilmington, Delaware and employs about 2,844 people.

How does Incyte make money?

As of 2026-Q2, Incyte's revenue breaks down across J A K A F I (59%), OPZELURA (28%), M I N J U V I (3%), ZYNYZ (3%). See the revenue-by-segment chart for the full mix.

How has Incyte's revenue and profitability trended?

Track Incyte's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 26, 2026.

Who are Incyte's main competitors?

Sterling groups Incyte in the Healthcare sector, alongside Biogen (BIIB), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX).

If I'm investing in Incyte, what similar companies should I consider?

If you are researching Incyte, also look at Biogen (BIIB), Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). You can compare all of them side by side or browse the full Healthcare sector on Sterling.